Wedbush Research Analysts Raise Earnings Estimates for CATX

Perspective Therapeutics, Inc. (NYSE:CATX) – Stock analysts at Wedbush boosted their Q1 2025 EPS estimates for Perspective Therapeutics in a research report issued on Wednesday, March 26th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per share of ($0.31) for the quarter, up from their previous forecast of ($0.37). Wedbush currently has a “Outperform” rating and a $11.00 target price on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.88) per share. Wedbush also issued estimates for Perspective Therapeutics’ Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.43) EPS, FY2025 earnings at ($1.53) EPS, FY2026 earnings at ($1.63) EPS and FY2027 earnings at ($1.73) EPS.

CATX has been the subject of a number of other reports. Brookline Capital Management raised shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Monday, March 10th. Scotiabank started coverage on shares of Perspective Therapeutics in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 price target for the company. Lifesci Capital upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research report on Thursday, March 6th. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Perspective Therapeutics in a report on Wednesday, March 19th. Finally, Royal Bank of Canada decreased their target price on Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating for the company in a research report on Thursday. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $14.44.

Perspective Therapeutics Price Performance

CATX opened at $2.20 on Monday. The business has a fifty day simple moving average of $2.94 and a 200-day simple moving average of $6.29. Perspective Therapeutics has a fifty-two week low of $2.19 and a fifty-two week high of $19.05.

Hedge Funds Weigh In On Perspective Therapeutics

A number of institutional investors have recently made changes to their positions in CATX. The Manufacturers Life Insurance Company boosted its holdings in Perspective Therapeutics by 8.9% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 20,514 shares of the company’s stock valued at $274,000 after purchasing an additional 1,672 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Perspective Therapeutics by 5.8% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 58,678 shares of the company’s stock valued at $783,000 after buying an additional 3,211 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in shares of Perspective Therapeutics by 7.4% in the fourth quarter. BNP Paribas Financial Markets now owns 51,094 shares of the company’s stock valued at $163,000 after buying an additional 3,529 shares during the period. Rhumbline Advisers grew its position in Perspective Therapeutics by 4.5% during the fourth quarter. Rhumbline Advisers now owns 94,992 shares of the company’s stock worth $303,000 after buying an additional 4,075 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its stake in Perspective Therapeutics by 3.4% during the fourth quarter. Bank of New York Mellon Corp now owns 143,469 shares of the company’s stock valued at $458,000 after acquiring an additional 4,693 shares during the period. 54.66% of the stock is currently owned by institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.